Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sernova names new president and CEO
Dr Toleikis is a seasoned and experienced biotechnology executive, with over 20 years of research, intellectual property, management and business experience in the pharmacology and biotechnology sectors, the
Dr Toleikis is a seasoned and experienced biotechnology executive, with over 20 years of research, intellectual property, management and business experience in the pharmacology and biotechnology sectors, the
Based on the company’s dual priming oligo (DPO) technology, the Seeplex diarrhea ACE detection tests for 10 bacteria (Salmonella species, Shigella species, Campylobacter species, Vibrio species, C difficile
The Malaysian Ministry of Health will provide a grant of MYR5 million to support this work which will be executed by GeneNews (Malaysia) Sdn Bhd, a subsidiary of
K2M has obtained the worldwide exclusive rights for all spinal applications of this material through an agreement with Promethean Surgical Devices in November 2008. In furtherance of K2M’s
The patent, which was granted in March 2009, covers the use of a specific polymer for the prophylactic and therapeutic treatment of rhinovirus infections. Andreas Grassauer, CEO and
For the first quarter of 2009, diluted earnings per share were $0.63, a decrease of 17.4%, compared to $0.76 for the first quarter of 2008. The company reported
Orphan drug designation entitles Antigenics to seven years of market exclusivity for Oncophage in the treatment of glioma patients in the event of market approval for this indication.
Revenues for the first quarter of 2009 were $3.16 million, compared to $2.76 million for the same period in 2008. First quarter 2009 revenues were primarily from Sangamo’s
As part of the amendment, Gen-Probe will acquire 4.9 million shares of newly issued DiagnoCure convertible preferred stock for $5 million, representing a premium of 19.8% over the
Mr Ennis was previously Revlon’s executive vice president, CFO and president of Revlon International. Mr Ennis and Mr Kennedy will both remain on the company’s board of directors.